Prostate Cancer Screening a Bad Idea!?

I think the studies referenced are fatally flawed for the following reasons

One, it presents a false dichotomy that there is only two types of prostate cancer, either the fast growing early onset type that killed Frank Zappa and the slow growing won't do you in at all type.

Second, it doesn't address the treatablity of prostate cancer very well. Is it a problem of the PSA and DRE tests that prostate cancer is not very tractable to treatment?

Surgery, radiation treatments of at least three different protocols that I know of as IANAD and numerous chemotherapy agents, indicate to me that there is not one treatment that is hands down better than anyother or effective even.

It compares the single shot PSA test against the no PSA test and does not encompass baseline PSA testing and PSA doubling time testing as a competative testing modality.

And lastly, I think the study encompasses too many subjects for not long enough period of time. I'd rather see a thousand patients in each cohort followed until death as long as it is ethical, meaning no denial of treatment.

Being in the group with a first degree relative who died of prostate cancer I may be too close the subject to be rational and objective but I am glad to know my PSA score is 0.1.
 
I think the studies referenced are fatally flawed for the following reasons

One, it presents a false dichotomy that there is only two types of prostate cancer, either the fast growing early onset type that killed Frank Zappa and the slow growing won't do you in at all type.

Well, it seems to be the case that, in the younger patient, the tumour tends to be more aggressive and, in the older patient, it tends to follow a more benign course.

Second, it doesn't address the treatablity of prostate cancer very well. Is it a problem of the PSA and DRE tests that prostate cancer is not very tractable to treatment?
Screening tests are worthwhile only if detecting cancer leads to earlier and effective treatment meaning improved survival rates not appreciably offset by serious side-effects. Unfortunately this has not been shown to be the case. There is also a problem with the actual screening tests. For example, less than 1 in 3 patients with elevated PSA actually turn out to have prostate cancer and 1 in 6 patients with normal PSA levels also have prostate cancer. This varies with age of course. DRE is positive only half the time in proven prostate cancer and 1 in 6 with positive DRE do not have prostate cancer.

Surgery, radiation treatments of at least three different protocols that I know of as IANAD and numerous chemotherapy agents, indicate to me that there is not one treatment that is hands down better than anyother or effective even.
The different treatments are used at different stages of the disease and in different types of patients. In other words one size does not fit all. For example, if the tumour is contained within the prostate prostatectomy is advised. Unless the patient is in poor health and then inplantation of radioactive rods into the prostate is advised. If the tumour has spread beyond the prostate, hormonal injections are often used. If it's spread into the spine radiotherapy to the spine is used to relieve pain and prevent conpression of the spinal cord.
I don't know about "numerous chemotherapy agents", I know of only two and they are both hormonal drugs.

It compares the single shot PSA test against the no PSA test and does not encompass baseline PSA testing and PSA doubling time testing as a competative testing modality.
One of the trials ran for 9 years, so the first year PSA is the base line PSA. I haven't read the trial details but I assume they take PSA velocity into account, although doubling time sounds a little to high (I seem to remember that a 25% increase over 12 months warrants a biopsy).
In the other trial, they looked at the common situation where a man fronts up for a PSA for the first time and it comes back elevated. Seems like a logical situation to study in my opinion

And lastly, I think the study encompasses too many subjects for not long enough period of time. I'd rather see a thousand patients in each cohort followed until death as long as it is ethical, meaning no denial of treatment.
You would be in a minority. You need an especially large number of patients where the evidence to date suggests that the benefits are likely to be small or minimal. Otherwise the outcome is unlikely to reach statistical significance. Also this study with this large patient base can continue indefinately into the future to provide ongoing data.

Being in the group with a first degree relative who died of prostate cancer I may be too close the subject to be rational and objective but I am glad to know my PSA score is 0.1.
My father did not die of his prostate cancer because his lung cancer got him first, but he very likely had metastatic disease because his PSA was over 50 so it was only a matter of time. I haven't had mine done and will not do so until there is clear evidence of benefit.

regards,
BillyJoe
 
The issue of metastases is one that often gets over looked, and should be a factor to consider.

Very common for Prostate CA to metastasize to the bone. Once there, pain is an understatement, and then you will be pumped full of analgesics.

That should be considered, not just when the CA will "take you out".

TAM:)
 

ISF - Join now!

Every member here is approved by hand. No bots, no spam, just people who care about evidence and honest debate.

Membership is free!

Create your free account

Back
Top Bottom